Поздняя диагностика первичного гиперальдостеронизма в амбулаторной практике

1. Баланова Ю.А., Драпкина О.М., Куценко В.А., Имаева А.Э., Концевая А.В., Максимов С.А. с соавт. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространенности, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кардиоваскулярная терапия и профилактика. 2023;22(S8):105–120. (Balanova YuA, Drapkina OM, Kutsenko VA, Imaeva AE, Kontsevaya AV, Maksimov SA et al. Hypertension in the Russian population during the COVID-19 pandemic: Sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2023;22(S8):105–120 (In Russ.)).

EDN: YRUNUX. https://doi.org/10.15829/1728-8800-2023-3785

2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–80.

PMID: 34450083. PMCID: PMC8446938. https://doi.org/10.1016/S0140-6736(21)01330-1

3. Xu Z, Yang J, Hu J, Song Y, He W, Luo T et al.; Chongqing Primary Aldosteronism Study (CONPASS) Group. Primary aldosteronism in patients in China with recently detected hypertension. J Am Coll Cardiol. 2020;75(16):1913–22.

PMID: 32327102. https://doi.org/10.1016/j.jacc.2020.02.052

4. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C et al.; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293–2300.

PMID: 17161262. https://doi.org/10.1016/j.jacc.2006.07.059

5. Клинические рекомендации. Артериальная гипертензия у взрослых. Общероссийская общественная организация «Российское кардиологическое общество», Общероссийская общественная организация «Российское научное медицинское общество терапевтов». Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 62_3. Доступ: https://cr.minzdrav.gov.ru/preview-cr/62_3 (дата обращения – 25.04.2025). (Clinical guidelines. Arterial hypertension in adults. Russian Society of Cardiology, Russian Scientific Medical Society of Internal Medicine. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 62_3. URL: https://cr.minzdrav.gov.ru/preview-cr/62_3 (date of access – 25.04.2025) (In Russ.)).

6. Клинические рекомендации. Первичный гиперальдостеронизм. Общероссийская общественная организация «Российская ассоциация эндокринологов». Доступ: https://endoinfo.ru/upload/kr_pga_20.09.2021_4.pdf (дата обращения – 25.04.2025). (Clinical guidelines. Primary hyperaldosteronism. Russian Association of Endocrinology. URL: https://endoinfo.ru/upload/kr_pga_20.09.2021_4.pdf (date of access – 25.04.2025) (In Russ.)).

7. Hannemann A, Bidlingmaier M, Friedrich N, Manolopoulou J, Spyroglou A, Völzke H et al. Screening for primary aldosteronism in hypertensive subjects: Results from two German epidemiological studies. Eur J Endocrinol. 2012;167(1):7–15.

PMID: 22495491. https://doi.org/10.1530/eje-11-1013

8. Chao С-T, Wu V-C, Kuo C-C, Lin Y-H, Chang C-C, Chueh SJ et al. Diagnosis and management of primary aldosteronism: An updated review. Ann Med. 2013;45(4):375–83.

PMID: 23701121. https://doi.org/10.3109/07853890.2013.785234

9. Ferreira NS, Tostes RC, Paradis P, Schiffrin EL. Aldosterone, inflammation, immune system, and hypertension. Am J Hyperten. 2021;34(1):15–27.

PMID: 32820797. PMCID: PMC7891246. https://doi.org/10.1093/ajh/hpaa137

10. Schilbach K, Junnila RK, Bidlingmaier M. Aldosterone to renin ratio as screening tool in primary aldosteronism. Exp Clin Endocrinol Diabetes. 2019;127(2-03):84–92.

PMID: 30165708. https://doi.org/10.1055/a-0672-0836

11. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: Mechanistic links. Nat Rev Nephrol. 2019;15(6):367–85.

PMID: 31015582. PMCID: PMC7278043. https://doi.org/10.1038/s41581-019-0145-4

12. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50.

PMID: 29129575. https://doi.org/10.1016/S2213-8587(17)30319-4

13. Mulatero P, Stowasser M, Loh K-C, Fardella CE, Gordon RD, Mosso L et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045–50.

PMID: 15001583. https://doi.org/10.1210/jc.2003-031337

14. Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro M-C et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: A position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020;38(10):1919–28.

PMID: 32890264. https://doi.org/10.1097/ HJH.0000000000002510

15. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889–1916.

PMID: 26934393. https://doi.org/10.1210/jc.2015-4061

16. Young WF Jr. Diagnosis and treatment of primary aldosteronism: Practical clinical perspectives. J Intern Med. 2019;285(2):126–48.

PMID: 30255616. https://doi.org/10.1111/joim.12831

17. Zhu R, Shagjaa T, Rossitto G, Caroccia B, Seccia TM, Gregori D, Rossi GP. Exclusion tests in unilateral primary aldosteronism (ExcluPA) study. J Clin Endocrinol Metab. 2023;108(2):496–506.

PMID: 36373399. https://doi.org/10.1210/clinem/dgac654

18. Leung AA, Symonds CJ, Hundemer GL, Ronksley PE, Lorenzetti DL, Pasieka JL et al. Performance of confirmatory tests for diagnosing primary aldosteronism: A systematic review and meta-analysis. Hypertension. 2022;79(8):1835–44.

PMID: 35652330. PMCID: PMC9278709. https://doi.org/10.1161/hypertensionaha.122.19377

19. Демидова Т.Ю., Титова В.В. Сложности диагностики первичного гиперальдостеронизма. FOCUS Эндокринология. 2023;4(2):59–68. (Demidova TYu, Titova VV. Difficulties in diagnosing primary hyperaldosteronism. FOCUS Endokrinologiya = FOCUS Endocrinology. 2023;4(2):59–68 (In Russ.)).

EDN: ZIIQBY. https://doi.org/10.15829/1560-4071-2023-12

20. Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C et al.; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689–99.

PMID: 28576687. PMCID: PMC5572673. https://doi.org/10.1016/S2213-8587(17)30135-3

21. Ладыгина Д.О., Вастистова А.А., Шиленкова Е.С., Платонова Н.М., Бельцевич Д.Г., Фадеев В.В. Первичный гиперальдостеронизм: существующие проблемы и возможные решения. Фарматека. 2024;31(2):8–17. (Ladygina DO, Vastistova AA, Shilenkova ES, Platonova NM, Beltsevich DG, Fadeev VV. Primary hyperaldosteronism: Current problems and possible solutions. Farmateka. 2024;31(2):8–17 (In Russ.)).

EDN: XXGVLG. https://dx.doi.org/10.18565/pharmateca.2024.2.8-17

22. Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F et al. Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: A population-based retrospective cohort study. Hypertension. 2022;79(1):178–86.

PMID: 34657442. PMCID: PMC8664996. https://doi.org/10.1161/hypertensionaha.121.18118

23. Jaffle G, Gray Z, Krishnan G, Stedman M, Zheng Y, Han J et al. Screening rates for primary aldosteronism in resistant hypertension: A cohort study. Hypertension. 2020;75(3):650–59.

PMID: 32008436. https://doi.org/10.1161/hypertensionaha.119.14359

24. Zekarias K, Tessier KM. Screening rate for primary aldosteronism among patients with treatment-resistant hypertension: Retrospective analysis of current practice. Endocr Pract. 2022;28(3):271–75.

PMID: 34843971. PMCID: PMC8901447. https://doi.org/10.1016/j.eprac.2021.11.085

25. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60(10):820–25.

PMID: 3661395. https://doi.org/10.1016/0002-9149(87)91030-7